Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams

doi:10.1200/JCO.2007.12.5070

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Identifier:nobleid.org/w1/20260515/C57A09AF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C57A09AF.svg?ark=w1%2F20260515%2FC57A09AF)](https://nobleid.org/work/w1/20260515/C57A09AF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Identifier:nobleid.org/w1/20260515/C57A09AF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C57A09AF.svg?ark=w1%2F20260515%2FC57A09AF)](https://nobleid.org/work/w1/20260515/C57A09AF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work